- Home
- BMRC vs ARTV Comparison
BMRC vs ARTV Comparison
Compare BMRC & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- ARTV
- Stock Information
- Founded
- BMRC 1989
- ARTV 2019
- Country
- BMRC United States
- ARTV United States
- Employees
- BMRC N/A
- ARTV N/A
- Industry
- BMRC Major Banks
- ARTV
- Sector
- BMRC Finance
- ARTV
- Exchange
- BMRC Nasdaq
- ARTV NYSE
- Market Cap
- BMRC 334.0M
- ARTV 275.7M
- IPO Year
- BMRC N/A
- ARTV 2024
- Fundamental
- Price
- BMRC $24.07
- ARTV $9.85
- Analyst Decision
- BMRC Buy
- ARTV Strong Buy
- Analyst Count
- BMRC 3
- ARTV 5
- Target Price
- BMRC $23.33
- ARTV $21.25
- AVG Volume (30 Days)
- BMRC 54.4K
- ARTV 63.8K
- Earning Date
- BMRC 01-27-2025
- ARTV 11-12-2024
- Dividend Yield
- BMRC 4.16%
- ARTV N/A
- EPS Growth
- BMRC N/A
- ARTV N/A
- EPS
- BMRC N/A
- ARTV N/A
- Revenue
- BMRC $59,368,000.00
- ARTV $2,601,000.00
- Revenue This Year
- BMRC N/A
- ARTV N/A
- Revenue Next Year
- BMRC $13.06
- ARTV N/A
- P/E Ratio
- BMRC N/A
- ARTV N/A
- Revenue Growth
- BMRC N/A
- ARTV N/A
- 52 Week Low
- BMRC $14.11
- ARTV $9.68
- 52 Week High
- BMRC $27.11
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- BMRC 45.30
- ARTV N/A
- Support Level
- BMRC $22.95
- ARTV N/A
- Resistance Level
- BMRC $25.00
- ARTV N/A
- Average True Range (ATR)
- BMRC 0.81
- ARTV 0.00
- MACD
- BMRC -0.27
- ARTV 0.00
- Stochastic Oscillator
- BMRC 42.34
- ARTV 0.00
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.